BrainStorm Cell Shares Plunge 18.03% Amid FDA Trial Uncertainty

BrainStorm Cell(BCLI) shares plummeted 18.03% today, hitting their lowest level since September 2024, with an intraday decline of 27.03%.

BrainStorm Cell Therapeutics has submitted an Investigational New Drug (IND) amendment to the FDA for NurOwn®, which is intended to pave the way for a Phase 3b trial in ALS. This development is crucial as it may influence future stock performance depending on the trial's outcome and FDA decisions.

The stock has been on a downward trend, falling in 6 of the last 10 days, and is down by -32.33% over this period. The short-term trend indicates a further potential decline of -41.37% over the next three months. The stock holds several negative technical signals, including sell signals from both short and long-term moving averages, and is considered "very high risk" due to its volatility and oversold condition on the RSI14.